GILD
GILEAD SCIENCES, INC.
Latest Form 4:Sale$2.7MbyWELTERS ANTHONY (Director) · filed Aug 27, 2026
GILEAD SCIENCES, INC. (GILD) has 78 SEC Form 4 filings (156 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Aug 27, 2026.
The most active filer is Chairman & CEO O'Day Daniel Patrick with 13 filings. Insiders have net sold $24.9M over the trailing 6 months.
- Industry:Drug Manufacturers - General
- CEO:Daniel O'Day
- Employees:17,600
- HQ:Foster City, CA, US
- IPO:1992-01-22
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$84.0M
reported sales (SEC code S)
Unique Insiders
7
in the rolling window
Market Cap
$180.6B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
WELTERS ANTHONYFirst filing | Director | Sale | 18,000 | $2.7M | Aug 27 | SEC ↗ |
Bluestone JeffreyFirst in 7 months | Director | Sale | 5,000 | $725K | Aug 21 | SEC ↗ |
| Chief Comm & Corp Aff Officer | Sale | 28,000 | $3.9M | Aug 18 | SEC ↗ | |
| Chief Financial Officer | Sale | 3,000 | $415K | Aug 18 | SEC ↗ | |
| Chairman & CEO | Sale | 15,000 | $2.0M | Aug 4 | SEC ↗ | |
| Chief Financial Officer | Sale | 3,000 | $390K | Jul 16 | SEC ↗ | |
| Chief Comm & Corp Aff Officer | Sale | 3,000 | $390K | Jul 16 | SEC ↗ | |
| Chairman & CEO | Sale | 15,000 | $1.9M | Jul 2 | SEC ↗ | |
| Chief Financial Officer | Sale | 3,000 | $376K | Jun 16 | SEC ↗ | |
| Chief Comm & Corp Aff Officer | Sale | 3,000 | $372K | Jun 16 | SEC ↗ | |
| Chairman & CEO | Sale | 15,000 | $2.0M | Jun 2 | SEC ↗ | |
| Chief Financial Officer | Sale | 3,000 | $397K | May 18 | SEC ↗ | |
| Chief Comm & Corp Aff Officer | Sale | 28,000 | $3.7M | May 18 | SEC ↗ | |
| Chairman & CEO | Sale | 10,000 | $1.3M | Apr 29 | SEC ↗ | |
| Chief Comm & Corp Aff Officer | Sale | 3,000 | $423K | Apr 16 | SEC ↗ | |
| Chief Financial Officer | Sale | 3,000 | $423K | Apr 16 | SEC ↗ | |
| Chairman & CEO | Sale | 10,000 | $1.4M | Mar 30 | SEC ↗ | |
| Chief Comm & Corp Aff Officer | Sale | 3,000 | $433K | Mar 17 | SEC ↗ | |
| Chief Financial Officer | Sale | 3,000 | $433K | Mar 17 | SEC ↗ | |
| Chairman & CEO | Sale | 10,000 | $1.4M | Mar 2 | SEC ↗ | |
| Chief Comm & Corp Aff Officer | Sale | 28,000 | $4.3M | Feb 18 | SEC ↗ | |
| Chief Financial Officer | Sale | 3,000 | $463K | Feb 18 | SEC ↗ | |
| Chairman & CEO | Sale | 115,640 | $17.3M | Feb 6 | SEC ↗ | |
| Chairman & CEO | Sale | 10,000 | $1.4M | Jan 29 | SEC ↗ | |
| Chairman & CEO | Sale | 115,640 | $15.6M | Jan 26 | SEC ↗ | |
| Director | Sale | 5,000 | $618K | Jan 21 | SEC ↗ | |
| Chief Financial Officer | Sale | 3,000 | $373K | Jan 16 | SEC ↗ | |
| Chief Commercial Officer | Sale | 3,000 | $373K | Jan 16 | SEC ↗ | |
| Chairman & CEO | Sale | 10,000 | $1.2M | Dec 30 | SEC ↗ | |
| Chief Financial Officer | Sale | 3,000 | $366K | Dec 16 | SEC ↗ | |
| Chief Commercial Officer | Sale | 3,000 | $366K | Dec 16 | SEC ↗ | |
Kramer Kelly A.First filing | Director | Sale | 2,806 | $357K | Dec 1 | SEC ↗ |
Kramer Kelly A.First filing | Director | Sale | 2,805 | $357K | Dec 1 | SEC ↗ |
Bluestone JeffreyFirst filing | Director | Sale | 5,000 | $625K | Dec 1 | SEC ↗ |
| Chairman & CEO | Sale | 10,000 | $1.3M | Dec 1 | SEC ↗ | |
| Chief Commercial Officer | Sale | 28,000 | $3.5M | Nov 18 | SEC ↗ | |
| Chief Financial Officer | Sale | 2,500 | $313K | Nov 18 | SEC ↗ | |
Telman Deborah HFirst filing | EVP, Corporate Affairs & GC | Sale | 53,646 | $6.6M | Nov 13 | SEC ↗ |
| Chairman & CEO | Sale | 10,000 | $1.2M | Oct 29 | SEC ↗ | |
| Chief Commercial Officer | Sale | 3,000 | $354K | Oct 16 | SEC ↗ | |
| Chief Financial Officer | Sale | 2,500 | $295K | Oct 16 | SEC ↗ | |
O'Day Daniel PatrickFirst filing | Chairman & CEO | Sale | 10,000 | $1.1M | Sep 30 | SEC ↗ |
Dickinson Andrew DFirst filing | Chief Financial Officer | Sale | 2,500 | $284K | Sep 16 | SEC ↗ |
Mercier JohannaFirst filing | Chief Commercial Officer | Sale | 3,000 | $341K | Sep 16 | SEC ↗ |
Congress trading GILD
See timeline →- DRep. Ro KhannaSale$1,001 - $15,0002026-07-07
- RSen. Tommy TubervillePurchase$1,001 - $15,0002024-05-10
- DRep. Jared MoskowitzPurchase$1,001 - $15,0002026-05-06
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Related companies
GILEAD SCIENCES, INC. is in the Healthcare sector.